PetMed Express ($PETS) announced its net revenue for the quarter ended March 31, 2017 were $63.0 million, compared to $55.4 million for the quarter ended March 31, 2016. The company’s for the quarter ended March 31, 2017 was $7.5 million, or $0.37 diluted per share, compared to net income of $5.4 million, or $0.27 diluted per share, for the same quarter the prior year. Its full year net income stood at $23.8 million, or $1.17 diluted per share.
Kite Pharma Inc. ($KITE) reported its first quarter loss at $90.4 million or $1.74 per share. The company posted revenue of $9.8 million for the period. Its research and development expenses were $65.9 million for the first quarter of 2017, which includes $12.7 million of non-cash stock-based compensation expense. As of March 31, 2017, Kite had $804.0 million in cash, cash equivalents, and marketable securities.